echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > 【OC Archives】Combined with a variety of underlying diseases, Nirapali decisively started to provide sustained benefits for patients with advanced ovarian cancer and liver dysfunction

    【OC Archives】Combined with a variety of underlying diseases, Nirapali decisively started to provide sustained benefits for patients with advanced ovarian cancer and liver dysfunction

    • Last Update: 2021-12-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    The preferred treatment mode for ovarian cancer is cytoreductive surgery combined with platinum-based chemotherapy


    Professor Wei Jihong

    Wei Jihong

    Master of Medicine, Sun Yat-sen University

    Chief Physician of Gynecology, Jiangmen Central Hospital

    Member of the Hysteroscopy Group of the Gynecological Endoscopy Branch of the Guangdong Medical Association

    Member of the Female Reproductive Surgery Branch of Guangdong Plastic Surgery Association

    Medical status, profession and achievements: 21 years of experience in gynecology, good at standardized diagnosis and treatment of gynecological benign and malignant tumors; good at laparoscopic minimally invasive surgery for gynecological benign and malignant tumors, hysteroscopic minimally invasive surgery for various uterine cavity diseases, and cervical diseases He has rich experience in the diagnosis and treatment of endocrine diseases such as genital malformations, menstrual abnormalities, and infertility


    Case sharing

    Case sharing

    one

    one

    Case review

    Case review

    basic information

    basic information

    The patient was a female with a 50-year-old age of onset.


    After treatment

    After treatment

    The first stage: neoadjuvant chemotherapy + surgery + postoperative chemotherapy

    The first stage: neoadjuvant chemotherapy + surgery + postoperative chemotherapy

    The patient came to the hospital on June 18, 2020 due to "lower abdominal distension for 1 month"


    Gynecological examination revealed: normal vulvovaginal development, mild cervix inflammation, normal uterus size, uterine body palpation is not clear, posterior wall and rectal fossa and nodular induration, left adnexal area palpable and a hard mass about 12× 10×10cm, the border is not clear, the movement is not good, and there is no tenderness; the right appendage is not palpable


    Initial diagnosis: ovarian serous papillary carcinoma


    NACT uses the TC regimen, and mild liver damage begins to occur after a course of chemotherapy


    Evaluation after two passes of NACT, gynecological examination: normal vulvovaginal development, mild cervix inflammation, normal uterine size, posterior wall and rectal fossa and nodular induration, left appendix area and a hard mass, about 5×6× 7cm, the border is not clear, the movement is not good, and there is no tenderness; the right appendage is not palpable


    Figure 1.


    Figure 1.


    The postoperative diagnosis was high-grade serous carcinoma of the ovary stage IIIB; viral hepatitis B (active stage)


    Figure 2.


    Figure 2.


    The second stage: PARP inhibitor maintenance treatment

    Genetic testing of the patient after chemotherapy indicated that BRCA1 +, HRD +


    Figure 3.


    Figure 3.


    Figure 4.
    Changes in blood routine during maintenance treatment with niraparib

    Figure 4.
    Changes in blood routine during maintenance treatment with niraparib Figure 4.
    Changes in blood routine during maintenance treatment with niraparib

    Figure 5.
    Enhanced CT of the pelvis and abdomen after Nirapali maintenance treatment (2021-06-01)

    Figure 5.
    Enhanced CT of the pelvis and abdomen after Nirapali maintenance treatment (2021-06-01) Figure 5.
    Enhanced CT of the pelvis and abdomen after maintenance Nirapali treatment (2021-06-01)

    two

    two

    Case summary

    Case summary

    This patient is ovarian serous papillary carcinoma stage IIIB.
    When choosing the initial treatment plan, consider the patient's severe tumor burden, low physical status ECOG score, poor surgical tolerance, and difficulty in achieving the ideal reduction.
    In order to reduce tumor burden and Difficulty of the operation, NACT treatment is given first
    .
    The patient has hepatitis B virus, poor resistance, HNV active stage, and severe liver damage after two courses of NACT, so he was treated with entecavir, bicyclol, compound glycyrrhizin, sodium glucuronate and other antiviral and liver protection treatments
    .
    IDS was performed later, and 4 courses of TC chemotherapy plus liver-protecting antiviral treatment were continued after the operation.
    The process went smoothly and the liver function did not appear to be abnormal again
    .
    After completing the initial treatment, in terms of maintenance treatment, considering that the patient's genetic test is positive for BRCA1, the liver cell function of viral hepatitis B (active phase) is poor, and the condition of the disease is comprehensively evaluated, and the maintenance treatment is selected niraparib
    .
    It has lasted for more than 9 months.
    The tumor markers were rechecked, blood routine and liver function were basically normal, and the patient's quality of life was good
    .
    No recurrence was seen, and the treatment effect was good
    .



    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.